Edwards Lifesciences Corporation (EW)

Market Cap	42.11B
Revenue (ttm)	5.44B
Net Income (ttm)	4.17B
Shares Out	589.80M
EPS (ttm)	6.97
PE Ratio	10.25
Forward PE	29.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,016,461
Open	72.16
Previous Close	71.62
Day's Range	71.15 - 72.99
52-Week Range	58.93 - 96.12
Beta	1.12
Analysts	Buy
Price Target	79.95 (+11.99%)
Earnings Date	Feb 11, 2025

About EW

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical struct...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Mar 27, 2000
• Employees: 15,800
• Stock Exchange: NYSE
• Ticker Symbol: EW
• Website: https://www.edwards.com

Financial Performance

In 2024, Edwards Lifesciences's revenue was $5.44 billion, a decrease of -9.41% compared to the previous year's $6.00 billion. Earnings were $4.17 billion, an increase of 197.68%.

Analyst Forecast

According to 21 analysts, the average rating for EW stock is "Buy." The 12-month stock price forecast is $79.95, which is an increase of 11.99% from the latest price.

Price Target

$79.95

(11.99% upside)

Analyst Consensus: Buy